List view / Grid view
triple negative breast cancer
Filter the results
The US FDA has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy), to treat triple-negative breast cancer in adult patients.
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...